JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty results and vaccine script trends for Comirnaty, Spikevax, and mResvia.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter